Oxford Immunotec  Proprietary tests for immune-regulated conditions

Perkin Elmer acquired Oxford Immunotec

Oxford Immunotec focused on developing and commercialising proprietary tests for immune-regulated conditions. On 2013 Oxford immunotec went public on NASDAQ via an IPO.

Industry

Diagnostics

Case facts

Location

United Kingdom

Status

Exit January 2021

Involved Team